PharmaMar stock tanks after PhIII ovarian cancer study flops
PharmaMar’s late-stage test of Zepsyre (lurbinectedin) has flunked the primary endpoint on progression-free survival for platinum-resistant ovarian cancer patients. And the news tanked the Spanish biotech’s share price, which plunged 32% on Friday as investors retreated in the wake of the failure.
PharmaMar had positioned the drug against topotecan or PLD (liposomal doxorubicin), but researchers say that the PFS was the same. They did spotlight an improved safety profile, though.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.